Re: Re: Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie’s disease

Article metrics

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012;187:2268–74.

  2. 2.

    Lipshultz LI, Goldstein I, Seftel AD, Kaufman GJ, Smith TM, Tursi JP, et al. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie’s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int. 2015;116:650–6.

  3. 3.

    Tsambarlis PN, Yong R, Levine LA. Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie’s disease. Int J Impot Res. 2019;31:15–9.

  4. 4.

    Anaissie J, Yafi FA, DeLay KJ, Traore EJ, Sikka SC, Hellstrom WJG, et al. Impact of number of cycles of collagenase clostridium histolyticum on outcomes in patients with Peyronie’s disease. Urology. 2017;100:125–30.

  5. 5.

    Yafi FA, Anaissie J, Zurawin J, Sikka SC, Hellstrom WJ. Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase clostridium histolyticum for Peyronie’s disease. J Sex Med. 2016;13:684–9.

  6. 6.

    Kuhlmann PK, DeLay KJ, Anaissie J, Hellstrom WJ, Yafi FA. Collagenase Clostridium histolyticum in the treatment of Peyronie's disease: patient selection and perspectives. Patient Prefer Adherence. 2017;11:431–48.

Download references

Author information

Correspondence to Peter Tsambarlis or Laurence A. Levine.

Ethics declarations

Conflict of interest

LAL is a speaker and consultant for Boston Scientific and Coloplast. PT declares that he has no conflicts of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark